GoAI
Get started
Lifecore Biomedical, Inc. logo

Lifecore Biomedical, Inc.

LFCR

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$4.54

+$0.02 · +0.44%

Aug 21, 4:00 PM ET

LFCR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

26

Weakening

Sentiment

52

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Paul Josephs
Listed since
Feb 15, 1996
Employees
382

Market position

Day range

Current $4.54

52-week range

Current $4.54

Open
$4.58
Previous close
$4.52
Volume
90.55K
0.48× average
Average volume
190.54K
Average daily volume
Market cap
170.29M USD
Beta
1.09
Market reference 1
50-day average
$4.854
-6.47% below average
200-day average
$6.0763
-25.28% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
432.5M USD
P/E (TTM)
-4.13×
P/B (TTM)
10.6×
P/S (TTM)
1.39×
EV / EBITDA
67.68×
Earnings yield
-2.00%
Free cash flow yield
2.03%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
29.68%
Operating margin
-2.12%
Net margin
-30.40%
Return on equity
43.35%
Return on assets
-2.65%
Return on invested capital
1.22%

Financial health

Debt / equity
9.64×
Current ratio
3.49×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends49%-7%-63%-119%Gross margin, FY2022: 35.11%Gross margin, FY2023: 27.10%Gross margin, FY2024: 32.63%Gross margin, FY2025: 31.27%Gross margin, FY2026: 35.34%Operating margin, FY2022: -10.60%Operating margin, FY2023: -21.11%Operating margin, FY2024: -6.90%Operating margin, FY2025: -13.38%Operating margin, FY2026: 7.51%Net margin, FY2022: -104.89%Net margin, FY2023: -96.41%Net margin, FY2024: 9.37%Net margin, FY2025: -30.04%Net margin, FY2026: -18.02%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 35.11%. Gross margin FY2023 27.10%. Gross margin FY2024 32.63%. Gross margin FY2025 31.27%. Gross margin FY2026 35.34%. Operating margin FY2022 -10.60%. Operating margin FY2023 -21.11%. Operating margin FY2024 -6.90%. Operating margin FY2025 -13.38%. Operating margin FY2026 7.51%. Net margin FY2022 -104.89%. Net margin FY2023 -96.41%. Net margin FY2024 9.37%. Net margin FY2025 -30.04%. Net margin FY2026 -18.02%.

Income trends

Revenue

34.17M USD-73.49%

Operating income

2.57M USD+19.81M USD

Net income

−6.16M USD+84.10%
Income trends across reported periods153.43M USD55.19M USD−43.04M USD−141.27M USDRevenue, FY2022: 111.27M USDRevenue, FY2023: 103.27M USDRevenue, FY2024: 128.26M USDRevenue, FY2025: 128.87M USDRevenue, FY2026: 34.17M USDOperating income, FY2022: −11.79M USDOperating income, FY2023: −21.8M USDOperating income, FY2024: −8.84M USDOperating income, FY2025: −17.25M USDOperating income, FY2026: 2.57M USDNet income, FY2022: −116.72M USDNet income, FY2023: −99.56M USDNet income, FY2024: 12.01M USDNet income, FY2025: −38.72M USDNet income, FY2026: −6.16M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 111.27M USD. Revenue FY2023 103.27M USD. Revenue FY2024 128.26M USD. Revenue FY2025 128.87M USD. Revenue FY2026 34.17M USD. Operating income FY2022 −11.79M USD. Operating income FY2023 −21.8M USD. Operating income FY2024 −8.84M USD. Operating income FY2025 −17.25M USD. Operating income FY2026 2.57M USD. Net income FY2022 −116.72M USD. Net income FY2023 −99.56M USD. Net income FY2024 12.01M USD. Net income FY2025 −38.72M USD. Net income FY2026 −6.16M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue34.17M USD128.87M USD128.26M USD103.27M USD111.27M USD
Cost of goods sold22.09M USD88.57M USD86.41M USD75.28M USD72.2M USD
Gross profit12.08M USD40.3M USD41.85M USD27.99M USD39.07M USD
Research and development1.54M USD8.26M USD8.58M USD8.74M USD7.84M USD
Selling, general, and administrative7.97M USD44.05M USD40.46M USD38.97M USD34.66M USD
Operating expenses9.51M USD57.54M USD50.69M USD49.78M USD50.86M USD
Interest income144K USD——68K USD81K USD
Interest expense7.7M USD21.84M USD18.09M USD17.65M USD15.55M USD
Depreciation and amortization4.83M USD8.03M USD8M USD13.18M USD18.06M USD
Operating income2.57M USD−17.25M USD−8.84M USD−21.8M USD−11.79M USD
Net income−6.16M USD−38.72M USD12.01M USD−99.56M USD−116.72M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 7 misses, 1 met estimate
Average EPS surprise
-61.91%
11 comparable reports
Latest EPS result
-0.19
Estimate -0.19 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.08-0.23-0.38-0.53Q4 '24MissQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ2 '26MissQ3 '26MetQ4 '26Estimate
Q4 2024, reported Oct 4, 2024: actual -0.49, estimate -0.46, surprise -6.52%, Miss. Q1 2025, reported Jan 2, 2025: actual -0.25, estimate -0.27, surprise +7.41%, Beat. Q2 2025, reported Apr 3, 2025: actual -0.47, estimate -0.14, surprise -235.71%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.1, estimate -0.09, surprise -11.11%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.29, estimate -0.3, surprise +3.33%, Beat. Q2 2026, reported May 6, 2026: actual -0.43, estimate -0.24, surprise -79.17%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.19, estimate -0.19, surprise 0.00%, Met estimate. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.298, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates37.9M32.51M27.12M21.73MQ4 '24BeatQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q4 2024, reported Oct 4, 2024: actual 24.71M USD, estimate 23.19M USD, surprise +6.54%, Beat. Q1 2025, reported Jan 2, 2025: actual 32.56M USD, estimate 29.75M USD, surprise +9.47%, Beat. Q2 2025, reported Apr 3, 2025: actual 35.15M USD, estimate 33.25M USD, surprise +5.73%, Beat. Q3 2025, reported Aug 7, 2025: actual 36.44M USD, estimate 35.38M USD, surprise +3.02%, Beat. Q4 2025, reported Nov 6, 2025: actual 31.11M USD, estimate 26.26M USD, surprise +18.47%, Beat. Q2 2026, reported May 6, 2026: actual 23.19M USD, estimate 25.96M USD, surprise -10.65%, Miss. Q3 2026, reported Aug 5, 2026: actual 23.19M USD, estimate 34.18M USD, surprise -32.14%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate 25.57M USD, surprise —, Comparison unavailable.

LFCR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LFCR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.63M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.92M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
708.56K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Vanguard Russell 2000 Value ETF logoVanguard Russell 2000 Value ETFVTWV
Market value
106.94K
Weight
0.01%
AUM
1.4B USD
Expense ratio
0.06%
Price / 1D
$198.38+0.34%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
60.9K
Weight
—
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%
Vanguard Russell 3000 ETF logoVanguard Russell 3000 ETFVTHR
Market value
8.5K
Weight
0.00%
AUM
6.1B USD
Expense ratio
0.06%
Price / 1D
$338.91+0.49%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
8.08K
Weight
0.00%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
ProShares Ultra Nasdaq Biotechnology logoProShares Ultra Nasdaq BiotechnologyBIB
Market value
5.81K
Weight
0.01%
AUM
103.78M USD
Expense ratio
1.19%
Price / 1D
$122.16+2.73%

Continue in GoAI

Research LFCR

research.disclaimer